Table 1.
Routine and SARS-CoV-2 vaccines, schedules, and cold storage volume per dose.
| Schedule | Cold storage tertiary packaging volume per dose (mL) | Cold storage secondary packaging volume per dose (mL) | Presentation | Product used | |
|---|---|---|---|---|---|
| Routine infant immunization | |||||
| Bacille Calmette-Guerin | Birth dose | 4.98 | 1.44 | 10 dose MDV | Japan BCG Laboratory |
| Hepatitis B | Birth dose | 12.56 | 2.86 | 10 dose MDV | Euvax B (paed) |
| Diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b (pentavalent) | 6, 10, and 14 weeks | 16.70 | 3.06 | 10 dose MDV | Eupenta |
| Polio (oral) | 6, 10, and 14 weeks | 6.22 | 1.40 | 10 dose MDV | PT Bio Farma (Persero) |
| Polio (inactivated) | 6 weeks | 23.95 | 4.00 | 5 dose MDV | Bilthoven Biologicals |
| Pneumococcal (conjugate) | 6, 10, and 14 weeks | 36.28 | 3.60 | 4 dose MDV | Pfizer |
| Rotavirus | 6 and 10 weeks | 49.45 | 46.30 | 1 dose SDV | Merck |
| Measles-rubella | 9–12 months, 13–24 months | 9.84 | 2.11 | 10 dose MDV | Serum Institute of India Pvt. Ltd. |
| Tetanus-diphtheria | 13–24 months | 9.47 | 2.38 | 10 dose MDV | PT Bio Farma (Persero) |
| Meningococcal A (conjugate) | 13–24 months | 9.84 | 2.11 | 10 dose MDV | Serum Institute of India Pvt. Ltd. |
| Yellow fever | 13–24 months | 3.59 | 2.99 | 10 dose MDV | Bio-Manguinhos/Fiocruz |
| Routine child immunization | |||||
| HPV (girls only) | 2 doses from 9 to 14 years | 7.61 | 4.84 | 2 dose MDV | GlaxoSmithKline Biologicals SA |
| Tetanus-diphtheria | 9–14 years | 9.47 | 2.38 | 10 dose MDV | PT Bio Farma (Persero) |
| SARS-CoV-2 immunization targeting risk groups | |||||
| ≥65 years | 2 doses, 1 month apart | 2.61 | 2.10 | 10 dose MDV | AstraZeneca/Oxford University SARS-CoV-2 vaccine characteristics produced by Serum Institute of India |
| Healthcare workers | 2 doses, 1 month apart | 2.61 | 2.10 | 10 dose MDV | AstraZeneca/Oxford University SARS-CoV-2 vaccine characteristics produced by Serum Institute of India |
| Chronic diseases | 2 doses, 1 month apart | 2.61 | 2.10 | 10 dose MDV | AstraZeneca/Oxford University SARS-CoV-2 vaccine characteristics produced by Serum Institute of India |
Notes:
-
1.Vaccines and schedules are from WHO Immunization Tables except SARS-CoV-2 vaccines [38]. SARS-CoV-2 vaccines use the dose schedule for AstraZeneca/Oxford University SARS-CoV-2 vaccine characteristics produced by Serum Institute of India, which is similar to other licensed SARS-CoV-2 vaccines in Europe and the United States.
-
2.Tertiary and secondary packaging volumes per dose from WHO Prequalified Vaccines Database with the exception of SARS-CoV-2 vaccines [19].
-
3.SARS-CoV-2 cold storage volume per dose use AstraZeneca/Oxford University SARS-CoV-2 vaccine characteristics produced by Serum Institute of India.
-
4.HPV vaccination programs generally target girls only aged 9 through 14 years [38]. For this simulation, we assumed the full HPV immunization series was given to girls 9 years of age.